RE:RE:RE:$5.25 millionYes, poof, Chiesi Global Rare Diseases is in the rare disease business. There are so many companies that claim to be in the rare disease space that the term has lost most of its meaning.
And, yes, Chiesi, take the EGF stuff. The Midatech "merger" valued the Cresence stuff at $250,000.
Then Bioasis would have to focus on advancing xB3, what the company should have been doing for the last 15 years.
jd